“One Medicine” evolving in the regenerative medicine era

Robert J Harman
Vet-Stem Inc, USA

The concept of “One Medicine” is deeply rooted in history but is principally focused on the area of zoonotic diseases. The emergence of cell-based therapy has opened the door for a much broader application of the concept of shared biology. Whereas animals may carry diseases that are transmitted to man, and therefore should be carefully studied, all mammals share similar stem cell biology and clinical and experimental data from animals can be used as more realistic predictors of cell therapy outcomes in human clinical studies. This presentation will explore the new and evolving dimensions of “One Medicine” and how the sharing of data and resources between commercial and academic, and human and veterinary stakeholders will benefit all species of patients.

Biography

Robert J Harman founded and is the CEO of Vet-Stem, the first US-based commercial veterinary stem cell company. For 15 years prior to that, he was the CEO of HTI-Bio-Services, a preclinical research company for veterinary and human pharmaceutical development. He has authored more than 500 contract study reports for animal health companies throughout the world and for submission to the FDA and USDA in support of the development of new animal and human health products. He received his DVM and master’s degree from the University of California at Davis in 1982.

bharman@vet-stem.com